Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-GUARD in Hospitalized Patients with Moderate COVID-19
NCT04454398Phase 1Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of COVI-GUARD in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Sorrento Therapeutics. Primary endpoints: Incidence of adverse events at Day 60, All-cause mortality at Day 60 and 4 more. Planned start Sep 2020; status: withdrawn.
02
Drugs
COVI-GUARD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04454398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454398.